Search research articles
Contact Us
Filters
Showing results (81-90 of 162) with videos related to
Page
of 17
Sort By:
Current Gastroenterology Reports
|
March 6, 2014
Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives
Niels Vande Casteele, Brian G Feagan, Ann Gils, et al.
Alimentary Pharmacology & Therapeutics
|
August 16, 2018
Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing
Bram Verstockt, Gitte Moors, Sumin Bian, et al.
Thrombosis Research
|
March 12, 2011
Characterization of a panel of monoclonal antibodies toward mouse PAI-1 that exert a significant profibrinolytic effect in vivo
Britt Van De Craen, Ilse Scroyen, Rana Abdelnabi, et al.
Thrombosis and Haemostasis
|
August 3, 2002
Characterization and comparative evaluation of a novel PAI-1 inhibitor
Ann Gils, Jean-Marie Stassen, Herbert Nar, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
March 11, 2020
Evaluating an easy sampling method using dried blood spots to determine vedolizumab concentrations
Sumin Bian, Nathalie Van den Berghe, Liesbeth Vandersmissen, et al.
Inflammatory Bowel Diseases
|
August 3, 2019
A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis
Erwin Dreesen, Wannee Kantasiripitak, Iris Detrez, et al.
British Journal of Clinical Pharmacology
|
February 19, 2021
The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases
Wannee Kantasiripitak, Bram Verstockt, Dahham Alsoud, et al.
Thrombosis Research
|
December 20, 2011
Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1
Britt Van De Craen, Ilse Scroyen, Christine Vranckx, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
February 4, 2014
Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy
Filip Baert, David Drobne, Ann Gils, et al.
Thrombosis Research
|
September 7, 2014
Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays
Lize Bollen, Marijke Peetermans, Miet Peeters, et al.
Page
of 17
Search research articles
Search
Showing results (81-90 of 162) with videos related to
Sort By:
Page
of 17
Current Gastroenterology Reports
|
March 6, 2014
Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives
Niels Vande Casteele, Brian G Feagan, Ann Gils, et al.
Alimentary Pharmacology & Therapeutics
|
August 16, 2018
Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing
Bram Verstockt, Gitte Moors, Sumin Bian, et al.
Thrombosis Research
|
March 12, 2011
Characterization of a panel of monoclonal antibodies toward mouse PAI-1 that exert a significant profibrinolytic effect in vivo
Britt Van De Craen, Ilse Scroyen, Rana Abdelnabi, et al.
Thrombosis and Haemostasis
|
August 3, 2002
Characterization and comparative evaluation of a novel PAI-1 inhibitor
Ann Gils, Jean-Marie Stassen, Herbert Nar, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
March 11, 2020
Evaluating an easy sampling method using dried blood spots to determine vedolizumab concentrations
Sumin Bian, Nathalie Van den Berghe, Liesbeth Vandersmissen, et al.
Inflammatory Bowel Diseases
|
August 3, 2019
A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis
Erwin Dreesen, Wannee Kantasiripitak, Iris Detrez, et al.
British Journal of Clinical Pharmacology
|
February 19, 2021
The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases
Wannee Kantasiripitak, Bram Verstockt, Dahham Alsoud, et al.
Thrombosis Research
|
December 20, 2011
Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1
Britt Van De Craen, Ilse Scroyen, Christine Vranckx, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
February 4, 2014
Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy
Filip Baert, David Drobne, Ann Gils, et al.
Thrombosis Research
|
September 7, 2014
Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays
Lize Bollen, Marijke Peetermans, Miet Peeters, et al.
Page
of 17